TriangleCyclophosphamide (NCT06083922)
Cyclophosphamide trial for Multiple Myeloma (NCT06083922). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed myeloma and cast nephropathy with severe kidney impairment. A separate cohort enrolls other plasma-cell-related kidney disorders, excluding AL amyloidosis.
The idea: daratumumab targets CD38, bortezomib blocks cellular protein disposal, and cyclophosphamide disrupts DNA replication. They join dexamethasone for eight planned cycles. Daratumumab is injected under the skin. Later transplant or maintenance depends on suitability and physician judgment. Researchers assess kidney response and safety.
This phase 2 study plans 20 patients. Hani Hassoun leads at MSK, New York; eight US locations recruit, some with limited activities.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.